topic about cancer diagnostics or therapeutics, with therapeutics to include any type of treatment (e.g., drug, device, etc.)
Cancer is a significant opportunity for the development of tissue engineering and cell therapies, but it is more than just an opportunity currently, since many companies are active and the market for cancer cell/tissue therapies already stands at nearly $500 million.
Currently, OSI Pharmaceuticals has a commanding lead in this area, with its Tarceva being [...]
The use of autologous, allogeneic and xenogeneic cells and tissues, the use of biomaterials, cell scaffolding and other approaches to tissue repair and regeneration has become part of arsenal of a number of clinical specialties, with high caseload and market revenue in these areas. In particular, orthopedics and skin applications are well established. And, while [...]
Our research into the products, technologies, companies and markets for tissue engineering and cell therapy has revealed that the 2009 market was at $6.9 billion. The market has grown dramatically, in commercialized products and company activity, over the past few years and is on an accelerated growth rate as technology hurdles are overcome and clinical [...]
The continued evolution of medical technologies is making it increasingly difficult, almost moot, to distinguish a medical device from other therapeutics. In Science Translational Medicine November 30, 2009, Harvard scientists report on the use of a polymer disc that stimulates an immune response that in turn shrinks tumors:
In a new approach to fighting cancer, scientists [...]
Below are select technologies under development at recently identified medtechs startups:
Scaffold for regeneration of functional bone tissues.
Autologous, adipose-derived stem cells for treatment of traumatic brain injury and chronic obstructive pulmonary disease.
Device company developing technologies to improve the safety and efficiency of chemotherapy.
Developing stem cell therapies.
Devices to locate and protect nerves during surgery.
Minimally invasive (endoscopic) spine [...]
The level of investment in medical technology has been erratic of late, with July and August financings each totaling in excess of $400 million, while October financings barely crossed $200 million (and would have been much less if not for a $40 million by Direct Flow Medical and $55 million by TransEnterix). See the trend. [...]
Medical technology startup companies that we identified during the month of October 2009 are developing the following specific technologies:
Diagnostic imaging in urology and oncology.
Endoscopic tissue management technology.
Esophageal monitoring device to replace peripheral artery catheter.
Products for treatment of fecal incontinence and GERD.
Surgical instrumentation to reduce trauma of surgery.
Suction device for use in sleep breathing disorders.
Fully absorbable [...]
The global market for medical devices is $200 billion opportunity and at least 13% of this market involves products that provide the controlled application of energy to tissue. The segment is dominated by high technology products ranging from devices that can heat and cool tissue over a 600° C temperature range of -200° C to [...]
Below are listed the products and technologies that are the focus of recently identified medtech startups, some of these companies being only weeks old.
Development of a debridement device using ice particles
Developing ultrasound ablation catheter for treating atrial fibrillation
Advanced damaged tissue care systems for wound care
System for detecting endothelial dysfunction as a precursor to cardiovascular disease
Drug [...]
Surgical management of soft tissues via "ablation" therapies, in which alternative energy types (radiation, electrosurgcal, ultrasound, etc.) are applied to excise, destroy, or otherwise produce a therapeutic effect at the tissue level has undergone a proliferation in development with all of these alternatives vying for caseload in clinical applications as diverse as tumor ablation, arrhythmia [...]
Contact:
